Pzena Investment Management LLC Increases Stock Position in Globe Life Inc. $GL

Pzena Investment Management LLC lifted its position in shares of Globe Life Inc. (NYSE:GL) by 5.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,026,246 shares of the company’s stock after purchasing an additional 50,199 shares during the period. Pzena Investment Management LLC’s holdings in Globe Life were worth $142,823,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Hilton Head Capital Partners LLC purchased a new stake in Globe Life in the 4th quarter valued at about $30,000. CYBER HORNET ETFs LLC purchased a new position in shares of Globe Life in the 2nd quarter worth approximately $28,000. MUFG Securities EMEA plc bought a new position in shares of Globe Life in the second quarter valued at approximately $31,000. Torren Management LLC bought a new position in shares of Globe Life in the fourth quarter valued at approximately $37,000. Finally, AdvisorNet Financial Inc increased its position in shares of Globe Life by 41.1% during the first quarter. AdvisorNet Financial Inc now owns 316 shares of the company’s stock valued at $44,000 after acquiring an additional 92 shares during the last quarter. 81.61% of the stock is currently owned by hedge funds and other institutional investors.

Globe Life Price Performance

Shares of NYSE GL opened at $180.17 on Thursday. The stock has a market cap of $13.99 billion, a PE ratio of 12.46 and a beta of 0.47. Globe Life Inc. has a fifty-two week low of $116.73 and a fifty-two week high of $182.32. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.07 and a current ratio of 0.07. The stock has a fifty day moving average of $160.03 and a 200-day moving average of $148.34.

Globe Life (NYSE:GL) last issued its earnings results on Wednesday, April 22nd. The company reported $3.43 EPS for the quarter, missing the consensus estimate of $3.46 by ($0.03). The company had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.56 billion. Globe Life had a return on equity of 20.94% and a net margin of 19.38%.The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.07 EPS. Globe Life has set its FY 2026 guidance at 15.400-15.90 EPS. Equities research analysts anticipate that Globe Life Inc. will post 15.64 earnings per share for the current year.

Globe Life Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Monday, July 6th will be issued a $0.33 dividend. This represents a $1.32 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Monday, July 6th. Globe Life’s dividend payout ratio is presently 9.13%.

Insider Buying and Selling

In related news, CFO Thomas Peter Kalmbach sold 15,637 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $153.65, for a total transaction of $2,402,625.05. Following the completion of the transaction, the chief financial officer owned 45,335 shares of the company’s stock, valued at approximately $6,965,722.75. The trade was a 25.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Frank M. Svoboda sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $156.68, for a total transaction of $3,133,600.00. Following the sale, the chief executive officer directly owned 54,020 shares in the company, valued at $8,463,853.60. This trade represents a 27.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 124,187 shares of company stock valued at $19,529,414 in the last three months. Insiders own 2.11% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Weiss Ratings raised Globe Life from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 13th. Keefe, Bruyette & Woods reaffirmed a “moderate buy” rating and set a $168.00 target price on shares of Globe Life in a research report on Thursday, March 26th. Truist Financial lifted their target price on Globe Life from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Wells Fargo & Company boosted their price target on shares of Globe Life from $171.00 to $172.00 and gave the stock an “overweight” rating in a report on Friday, April 10th. Finally, Piper Sandler increased their price target on shares of Globe Life from $167.00 to $175.00 and gave the company an “overweight” rating in a research report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $175.89.

About Globe Life

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.